Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Table 2 CEA results of base-case

Treatment strategy	Outcomes of Partitioned Survival Models			Incremental Changes
Treatment strategy	Intervention: Pemigatinib	Comparator 1: mFOLFOX	Comparator 2: 5-FU	Pemigatinib vs. mFOLFOX	Pemigatinib vs 5-FU
Cost	4,177,572	749,130	524,472	3,428,442	3,653,100
Total cost of PF state	3,780,469	577,970	369,229	3,202,499	3,411,240
Medication cost	3,514,168	187,675	63,430	3,326,493	3,450,738
Nonmedication cost	276,301	390,294	305,799	− 123,993	− 39,498
Total cost of PD state	397,103	171,160	155,243	225,943	241,860
LY
PF state	0.81	0.46	0.36	0.35	0.45
Overall	1.61	0.80	0.67	0.81	0.94
QALY
PF state	0.61	0.33	0.26	0.28	0.35
Overall	1.15	0.56	0.47	0.59	0.68
ICER
Incremental cost per LY gained				4,238,063	3,888,175
Incremental cost per QALY gained				5,814,700	5,380,241
INMB
LY				− 1,059,333	− 901,589
QALY				− 1,701,710	− 1,664,647
EVPI/person				43,139	23,608

Costs listed in 2022 Taiwan dollars
EVPI expected value of perfect information, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, LY life-year, PD progressed disease, PF progression free, QALY quality-adjusted life-year

ISSN: 1478-7547